Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Rizzoli

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Haematologica|February 16, 2005
Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cellsNicola Giuliani, Simona Colla, Francesca Morandi, et al.
Cancer Research|January 28, 2004
Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?Nicola Giuliani, Simona Colla, Vittorio Rizzoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
The p53 family protein p73 provides new insights into cancer chemosensitivity and targetingPaolo Lunghi, Antonio Costanzo, Laura Mazzera, et al.
Haematologica|November 13, 2008
Impact of XIAP protein levels on the survival of myeloma cellsGrégoire Desplanques, Nicola Giuliani, Roberto Delsignore, et al.
Blood|January 13, 2006
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patientsNicola Giuliani, Francesca Morandi, Sara Tagliaferri, et al.
Tumori|April 26, 2007
A translocation t(4; 13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenomaGabriella Sammarelli, Marco Zannoni, Sabrina Bonomini, et al.
Biochemical Pharmacology|March 26, 2002
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cellsAnnamaria Buschini, Chiara Alessandrini, Anna Martino, et al.
Cancer Research|August 19, 2007
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironmentNicola Giuliani, Francesca Morandi, Sara Tagliaferri, et al.
Blood|June 4, 2005
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiationNicola Giuliani, Simona Colla, Francesca Morandi, et al.
Experimental Hematology|October 28, 2010
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxideManuela Abeltino, Sabrina Bonomini, Marina Bolzoni, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Haematologica|February 16, 2005
Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cellsNicola Giuliani, Simona Colla, Francesca Morandi, et al.
Cancer Research|January 28, 2004
Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?Nicola Giuliani, Simona Colla, Vittorio Rizzoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
The p53 family protein p73 provides new insights into cancer chemosensitivity and targetingPaolo Lunghi, Antonio Costanzo, Laura Mazzera, et al.
Haematologica|November 13, 2008
Impact of XIAP protein levels on the survival of myeloma cellsGrégoire Desplanques, Nicola Giuliani, Roberto Delsignore, et al.
Blood|January 13, 2006
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patientsNicola Giuliani, Francesca Morandi, Sara Tagliaferri, et al.
Tumori|April 26, 2007
A translocation t(4; 13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenomaGabriella Sammarelli, Marco Zannoni, Sabrina Bonomini, et al.
Biochemical Pharmacology|March 26, 2002
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cellsAnnamaria Buschini, Chiara Alessandrini, Anna Martino, et al.
Cancer Research|August 19, 2007
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironmentNicola Giuliani, Francesca Morandi, Sara Tagliaferri, et al.
Blood|June 4, 2005
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiationNicola Giuliani, Simona Colla, Francesca Morandi, et al.
Experimental Hematology|October 28, 2010
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxideManuela Abeltino, Sabrina Bonomini, Marina Bolzoni, et al.
Pageof 5